Utrecht, Netherlands

Patrick Van Berkel

USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 6.4

ph-index = 6

Forward Citations = 193(Granted Patents)


Company Filing History:


Years Active: 2015-2024

Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Patrick Van Berkel

Introduction

Patrick Van Berkel is a prominent inventor based in Utrecht, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-based therapies. With a total of 14 patents to his name, Van Berkel has established himself as a key figure in the industry.

Latest Patents

Among his latest patents is the invention of heterodimeric antibody Fc-containing proteins and methods for their production. This innovation includes novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, along with new methods for producing these proteins. Another notable patent focuses on the modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains. This patent describes antibody variants that have either decreased or increased ability to mediate complement-dependent cytotoxicity due to modifications at the C-terminus of their heavy chains. The methods for generating such antibodies, as well as nucleotide constructs and host cells suitable for their production, are also detailed in this patent.

Career Highlights

Throughout his career, Patrick Van Berkel has worked with several notable companies, including Genmab A/S and Genmag A/S. His work in these organizations has contributed to advancements in therapeutic antibody development and production.

Collaborations

Van Berkel has collaborated with esteemed colleagues such as Paul Parren and Jan Van De Winkel. These partnerships have further enhanced his research and innovation in the field.

Conclusion

Patrick Van Berkel's contributions to biotechnology and his innovative patents have significantly impacted the development of antibody therapies. His work continues to influence the industry and pave the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…